Primary antifungal prophylaxis: decrease of invasive fungal disease incidence and reduction of risk factors in haematological patients in a 5‐year retrospective study

Abstract

PAP is necessary and efficient to prevent IFD in haematological patients, and the real-life PAP strategy is reasonable. Different drugs can be chosen, and it is better to start PAP as soon as neutropenia begins.

Intravenous-oral itraconazole versus oral posaconazole in preventing invasive fungal diseases for acute leukemia patients

“…When it comes to the PAP, triazoles are always popular. 7,15 In a previous study, the proportions of different PAP were 75.8% (triazoles), 13.1% (echinocandins), and 11.1% (AmB). 7 Due to the epidemiological shift toward mold infections worldwide, fluconazole has not been the preferred choice to prevent IFDs.…”

“…7,15 In a previous study, the proportions of different PAP were 75.8% (triazoles), 13.1% (echinocandins), and 11.1% (AmB). 7 Due to the epidemiological shift toward mold infections worldwide, fluconazole has not been the preferred choice to prevent IFDs. 14 Mold-active prophylaxis, including posaconazole, voriconazole, itraconazole, and others, has been listed in the recommendations 9,10 and has significantly reduced the incidence of IFDs.…”

“…14 Mold-active prophylaxis, including posaconazole, voriconazole, itraconazole, and others, has been listed in the recommendations 9,10 and has significantly reduced the incidence of IFDs. 6,7,16 Li et al 7 reported that PAP decreased the rate of IFDs (6.8% vs 17.9%, P = .000) and the IFD-related mortality (10.1% vs 29.7%, P = .000). However, the choice of PAP drugs has been a popular topic for years, because of the variable efficacy among different patient groups, regions, and centers.…”

Multimorbidity, not human immunodeficiency virus (HIV) markers predicts unplanned admission among people with HIV in regional New South Wales

“…In Australia, regional areas tend to have older populations of PWH. 39 Regional areas in Australia tend to have less availability of GP able to be accessed without direct patient cost, which may increase utilisation of EDs. There are also less GP able to prescribe ARV in regional areas, increasing the need for two prescribers for PWH.…”

Posaconazole versus Itraconazole as Prophylactic Antifungal Agents during Induction Chemotherapy for Acute Myeloid Leukemia: A Real-World Single Center Comparison

“…Additionally, it is now standard to use posaconazole as a prophylactic antifungal agent in induction chemotherapy for AML. However, some retrospective studies have reported that posaconazole has no significantly different effect on breakthrough IFD and 100-day mortality compared to other drugs [10,11]. This study aimed to compare the efficacy of posaconazole and itraconazole in the prevention of IFD in patients receiving first induction chemotherapy in a realworld setting.…”